82 results about "Poor prognosis" patented technology

Disclosures herein are directed to methods and compositions for predicting high- and low-risk liver disease in patients. Based on the results achieved from the methods and compositions disclosed herein, liver disease patients can be classified into a prognostic risk group, which enables early diagnosis and prevention of HCC and other lethal complications. Methods and compositions disclosed herein substantially improve the poor prognosis of subjects having or at risk for one or more liver diseases.

The invention provides a biomarker for predicting chemosensitivity of acute myelogenous leukemia and application of the biomarker, and belongs to the technical field of biological medicine. The leptin and fumaric acid provided by the invention can be used as biomarkers for predicting AML chemotherapy resistance. Wherein the leptin influences the chemotherapy sensitivity by regulating metabolic pathways such as mitochondrial OXPHOS and mitochondrial active oxygen mtROS; meanwhile, the invention also discloses a new mechanism that fumaric acid promotes BMSCs to transfer mitochondria to AML cells so as to enhance the OXPHOS level and induce Ara-C drug resistance. The levels of the two are obviously related to the chemotherapy reaction and prognosis stratification of the patient, so that early recognition of the patient with chemotherapy resistance or poor prognosis is facilitated. Leptin and fumaric acid can be detected in bone marrow plasma, the feasibility is high, and clinical transformation is facilitated. By detecting the level of leptin or fumaric acid in bone marrow of a patient, individualized treatment can be achieved, and the survival rate of the patient is increased.

The invention relates to application of WDR74 and / or ALYREF as molecular targets in esophageal squamous cell carcinoma diagnosis and treatment, and belongs to the technical field of biological medicine. Aiming at the problem that the esophageal squamous cell carcinoma lacks an effective targeted treatment means, the invention discovers that the expression quantity of WDR74 in tumor tissues is obviously higher than that in para-carcinoma tissues, and the high expression of WDR74 prompts poor prognosis of a patient, and reveals that WDR74 protein and ALYREF protein have specific binding, and the mRNA stability of EGFR is enhanced through ALYREF-mediated m5C RNA epigenetic modification, so that STAT3 phosphorylation is activated, and the treatment effect of the esophageal squamous cell carcinoma is enhanced. Further, the STAT3 is combined with the promoter region of the apoptosis-inhibiting gene MCL1, and finally cell apoptosis is inhibited and tumor formation is promoted. The invention provides a new molecular target and a solution for developing a WDR74 and ALYREF targeting medicine for treating esophageal squamous cell carcinoma and related diagnosis and prognosis evaluation products.

The invention discloses an application of HILAR in preparation of a product for predicting non-small cell lung cancer prognosis and lung adenocarcinoma metastasis risk, and particularly provides an application of a reagent for detecting the expression level of HILAR in preparation of a related kit, and a detection method comprises qPCR or RNA-FISH. Clinical sample analysis shows that the expression of the HILAR in non-small cell lung cancer patients with metastasis is obviously higher than that of non-metastasis patients, and the high expression of the HILAR is closely related to poor prognosis of the patients; in-vitro function experiments prove that overexpression of HILAR can significantly enhance the migration and invasion ability of lung adenocarcinoma cells; an in-vivo animal model shows that overexpression of the HILAR can obviously promote the metastasis and colonization capability of lung adenocarcinoma cells in a mouse body. Results show that the HILAR can be used as an important biomarker for predicting non-small cell lung cancer metastasis and evaluating prognosis, and a solid experimental basis and application prospect are provided for developing related diagnostic kits.

The application discloses application of CPSF7 as an ovarian cancer treatment and prognosis target, and relates to the technical field of biological medicine.The application research finds that overexpression of CPSF7 is related to poor prognosis of ovarian cancer, indicating that CPSF7 can be used as a prognosis index and potential treatment target of ovarian cancer.Further research shows that CPSF7 promotes malignant progression of ovarian cancer by promoting proliferation, migration and invasion of ovarian cancer cells, and inhibition of CPSF7 expression can significantly inhibit proliferation, migration and invasion of ovarian cancer cells.The application also finds that UBE2K is one of key downstream targets of CPSF7 in the ovarian cancer cell-mediated carcinogenic process, and inhibition of UBE2K expression can weaken the overexpression of CPSF7 induced enhancement effect of ovarian cancer cell proliferation, migration and invasion.The application provides a new target for treatment and prognosis prediction of ovarian cancer, and has important clinical application value.

The invention provides a state prediction method and device for a traumatic patient, electronic equipment and a storage medium, and belongs to the technical field of artificial intelligence. The method comprises the following steps: acquiring state parameters of a traumatic patient, wherein the state parameters comprise multiple of gender, age, systolic pressure, diastolic pressure, noninvasive blood pressure average value, heart rate, respiratory rate and oxyhemoglobin saturation; standardizing the state parameters to obtain input parameters; inputting the input parameters into a prediction model to obtain a first prediction probability output by the prediction model; wherein the first prediction probability is the probability that the traumatic patient has hemorrhagic shock, the probability that the traumatic patient needs to be infused with erythrocyte products of more than a set unit, the probability that the traumatic patient needs to receive an operation within a set time or the probability that the traumatic patient has poor prognosis. According to the invention, the shock probability, the probability of infusing red blood cell products, the probability of needing operations or the probability of poor prognosis of the traumatic patient can be predicted according to the state parameters of the traumatic patient.

The invention relates to a biomarker combination for treating SHH subtype medulloblastoma, and aims to solve the problems that existing treatment targets are deficient, the curative effect is limited and precise treatment is insufficient. The invention reveals that an m6A-YTHDF2 signal axis is a novel treatment target of SHH-MB for the first time, the YTHDF2 regulates and controls the expression of a downstream target gene DENND2A through an m6A dependency mode, the high expression of the YTHDF2 is related to poor prognosis of a patient, and knock-down of the YTHDF2 can significantly inhibit the proliferation and balling ability of SHH-MB cells. According to the invention, the TET-ON regulated SHH-MB cell line capable of inducing to knock down YTHDF2 is constructed, and a tool is provided for drug screening; it is clear that a YTHDF2 inhibitor (such as DC-Y13-27 and the like) can achieve the anti-tumor effect by down-regulating DENND2A expression, and the drug sensitivity of SHH-MB tumor cells to a Hedgehog signal channel small molecule inhibitor Vismodegib (GDC-0449) is improved.

The invention discloses a pancreatic cancer diagnosis marker and application thereof, and belongs to the technical field of biological medicines, a serological marker for pancreatic cancer diagnosis is thymosin beta-10, namely Tbeta10, a biomarker for pancreatic cancer diagnosis is a gene TMSB10 for coding the Tbeta10, the gene is 9168 in an NCBI database, a qRT-PCR upstream primer of the TMSB10 is shown as SEQ ID NO.1, a qRT-PCR downstream primer of the TMSB10 is shown as SEQ ID NO.2, the qRT-PCR downstream primer of the TMSB10 is shown as SEQ ID NO.1, the qRT-PCR upstream primer of the TMSB10 is shown as SEQ ID NO.1, and the qRT-PCR downstream primer of the TMSB10 is shown as SEQ ID NO.2. Tbeta10 protein or TMSB10 gene high expression serves as a biomarker for diagnosis and poor prognosis of a pancreatic cancer patient, it is determined that the content of Tbeta10 in serum of the pancreatic cancer patient is remarkably increased, the Tbeta10 protein or TMSB10 gene high expression serves as a serum marker for diagnosis and curative effect and prognosis monitoring of the pancreatic cancer, and the total survival rate of the pancreatic cancer patient is reduced; the TMSB10 is used as a biomarker for poor prognosis of pancreatic cancer patients.

The present invention includes methods for treating a FLT3 mutated proliferative disorder comprising: measuring expression of a mutated FLT3 and a one or more driver mutations in a nuclear transport protein that results in a loss of localization of the nuclear transport protein in a sample obtained from a tumor sample obtained from the patient, wherein the presence of the one or more genetic abnormalities indicates that the patient has a poor prognosis; and administering to the patient a therapeutically effective amount of Crenolanib or a pharmaceutically acceptable salt thereof, wherein the Crenolanib increases a chance of survival of the patient having both the mutated FLT3 and mutation in NPM1 or NUP98, wherein the Crenolanib, as shown below, is administered to a subject suffering from said disorder:

The invention discloses construction and application of a poor heart failure prognosis risk prediction model. Specifically, the invention provides a construction method of a poor heart failure prognosis risk prediction model, which comprises the following steps: (s1) providing a first data set which comprises poor heart failure prognosis risk marker data, the biomarker comprises the following metabolites from intestinal flora: trimethylamine oxide (TMAO), acetyl L-carnitine (ALC), choline chloride (CC), gamma-butyl betaine (gamma-BB) and L-carnitine (LC); and (s2) constructing a risk prediction model of acute attack or deterioration of the heart failure patient according to the risk marker data. The risk prediction model has excellent prediction capability of poor prognosis of heart failure.

The present application belongs to the technical field of biomarkers, and particularly relates to a breast cancer biomarker and application thereof. The present application first identifies long-chain non-coding RNA CCLA, and confirms that the expression of CCLA in triple-negative breast cancer tissue is significantly higher than that in normal tissue, and high expression is closely related to poor prognosis of patients. Through RT-qPCR verification and survival analysis of 81 TNBC clinical samples, the potential of CCLA as a specific biomarker of TNBC is confirmed, a new specific target for precise diagnosis and treatment of TNBC is provided, and the shortage of TNBC target points in the prior art is effectively overcome.

The application discloses application of SMOX in preparation of a colorectal cancer diagnosis or prognosis prediction product, and relates to the field of biotechnology.It is proved that the expression of SMOX in colon cancer and rectal cancer tissues is higher than that in normal tissues, and high expression of SMOX is related to poor prognosis of colon cancer.The application applies SMOX to diagnosis or prognosis prediction of colorectal cancer, thereby providing a new source for preparation of a colorectal cancer diagnosis or prognosis prediction product, and discovering new medical value of SMOX.

The invention belongs to the technical field of in-vitro diagnostic reagents for rapid detection of human pathogenic microorganisms, and particularly relates to a kit for rapid combined detection of multiple pathogen nucleic acids related to a dyspnea pregnancy outcome and application of the kit. The pathogen is selected from one or more of escherichia coli, candida albicans, candida glabrata, group B streptococcus, streptococcus gonorrhoeae, chlamydia trachomatis or ureaplasma urealyticum, and the kit comprises a pathogen and lactobacillus rapid detection micro-fluidic chip. A primer group for detecting the pathogen and the lactic acid bacillus nucleic acid and an array consisting of an amplification control and a blank control are fixed on the micro-fluidic chip. According to the present invention, the microfluidic chip rapid detection technology and the nucleic acid amplification technology are adopted to achieve the purposes of rapid detection and multiple detection so as to rapidly and conveniently determine the poor prognosis risk of the pregnant woman at present, timely take the specific measures, and avoid the occurrence of the poor prognosis.

This invention discloses the application of P4HB as a target in the preparation of therapeutic drugs for metastatic pleural and peritoneal effusions in multiple cancer types. Through combined single-cell transcriptomics and proteomics analysis, this invention revealed that P4HB is significantly overexpressed in metastatic pleural and peritoneal effusion lesions. Multiplex immunofluorescence and immunohistochemistry were used to perform in situ tissue validation in clinical samples of pleural and peritoneal effusions from breast cancer, lung cancer, gastric cancer, colorectal cancer, and ovarian cancer, clarifying the differential expression characteristics of P4HB in metastatic tumor cells and its correlation with poor prognosis. In patient-derived organoid models, targeting and inhibiting P4HB activity with small molecule inhibitors significantly reduced organoid growth capacity and survival rate, and showed a synergistic sensitizing effect on chemotherapeutic drugs. This invention reveals the use of P4HB as a therapeutic target for metastatic pleural and peritoneal effusions in multiple cancer types, providing a new target and direction for drug development in precision medicine.

The invention relates to application of a CTSD inhibitor in improvement of colorectal cancer immunotherapy sensitivity. A large number of studies find that CTSD is a gene which is extremely related to colorectal cancer immunotherapy, and the invention discloses an internal effect of CTSD in creating an immunosuppression environment in CRC (Cyclic Redundancy Check). The effectiveness of immunotherapy can be effectively enhanced by inhibiting the level of CTSD. Generally speaking, the high expression of CTSD as a cancer promoting factor of colorectal cancer is closely related to low immunotherapy effect of colorectal cancer and poor prognosis. By revealing the relevance between the CTSD gene and colorectal cancer occurrence and development and anti-PD-1 antibody treatment, the CTSD gene can be used for clinical curative effect difference and prognosis evaluation among individuals, accurate treatment is better achieved, and the CTSD gene has important clinical significance. A new drug treatment target is provided for clinical treatment of colorectal cancer, a new direction and theoretical basis are provided for subsequent drug research and development and the like, and certain clinical application value and market application prospects are achieved.

The invention provides a method and system for establishing a cancer pain prognosis prediction model, and the method comprises the steps: collecting cases, and selecting variable factors which need to be included in the construction of the prediction model; detecting the genotype of each SNP site by adopting gene sequencing; assigning values to dependent variable factors and independent variable factors; a prediction model is established based on Logistic regression analysis; and evaluating the prediction capability of the prediction model by using the Cox-Snell R score and the Neigore R score. The prediction model is established by detecting genotype combination analysis of SNP loci with a great cancer pain prognosis effect and combining clinical characteristics, biochemical indexes and gene detection results, individual prediction is used for each patient, cancer pain patients with poor prognosis are found timely and accurately, the drug test time is shortened, the identification speed is increased, and the detection efficiency is improved. The efficiency of determining the treatment effect of the cancer pain medicine is improved, and insufficient analgesia and serious adverse reaction are avoided.

The invention discloses a diffuse large B-cell lymphoma prognostic diagnosis marker combination and application thereof. The marker combination disclosed by the invention comprises TCF4 and AURKA. Bioinformatics exploration is utilized, immunohistochemical staining is further utilized to confirm that expression up-regulation of AURKA and TCF4 in clinical DLBCL cases is related to poor prognosis of patients, and the two molecules have a co-expression relationship with c-MYC. Researches prove that AURKA and TCF4 are markers for poor prognosis of DLBCL patients, TCF4 is a potential target spot in DLBCL treatment, a new prognostic marker is provided for DLBCL, and a theoretical basis is provided for further exploration of a treatment strategy of combined use of the AURKA and an AURKA inhibitor.

The invention relates to the field of biological medicine, in particular to application of sEV protein RAB7 in prognosis and treatment of triple negative breast cancer. The invention finds that the expression of RAB7 in a patient with early-stage TNBC transfer is obviously higher than that of a patient without transfer, and the RAB7 is related to poor prognosis and advanced TNBC patients. The invention discloses a molecular mechanism of the sEV protein RAB7 in tumor progression and immune system regulation, and shows that the targeted RAB7 and anti-PD-1 combined treatment has clinical potential. The sEV protein RAB7 is a potential novel prognosis prediction and recurrence and metastasis monitoring marker for non-invasive detection of TNBC and a new target for treatment of TNBC.

The invention discloses a method for establishing an antibody-mediated autoimmune encephalitis prognosis evaluation column diagram model. The method comprises the following steps: collecting patient demographic data, clinical manifestation, vEEG, multi-mode MRI, cognition and emotion scale, blood and cerebrospinal fluid assay and follow-up data; screening independent risk factors and protection factors through single-factor and multi-factor binary Logistic regression; and establishing a column graph prediction model according to the screened factors, and evaluating the performance of the model through an ROC curve, a correction curve and DCA. The model shows abnormal mental behaviors, the epileptic seizure type FBTCS is an independent risk factor of poor prognosis, normal number of neutrophils in blood is a protection factor, marginal system atrophy is an independent risk factor of transformation of chronic epilepsy, and normal number of lymphocytes in blood is a protection factor. The method can provide quantitative and visual individualized prognosis evaluation for the antibody-mediated autoimmune encephalitis patients, and can assist in early precise diagnosis and treatment.

The invention relates to the technical field of medical diagnosis, in particular to application of a detection reagent of CROT protein in a product for prognosis of nasopharyngeal carcinoma risk, and the amino acid sequence of the CROT protein is shown as SEQ ID NO.1. The subject with the prognosis nasopharynx cancer risk is a person, and the detected sample is the tissue of the subject. The high expression of the CROT protein is related to the occurrence and malignant growth behavior of nasopharyngeal carcinoma, and compared with a healthy control, the high expression of the CROT protein indicates that a subject suffers from nasopharyngeal carcinoma or has the risk of nasopharyngeal carcinoma; if the CROT protein expression in the tissue of the nasopharyngeal carcinoma patient is increased, the patient is judged as poor prognosis; if the CROT protein expression in the tissue of the nasopharyngeal carcinoma patient is reduced, the patient is judged to be good in prognosis.

The invention discloses application of CPSF7 as an ovarian cancer treatment and prognosis target, and relates to the technical field of biological medicine. The research finds that the overexpression of the CPSF7 is related to the poor prognosis of the ovarian cancer, which indicates that the CPSF7 can be used as a prognosis index and a potential treatment target of the ovarian cancer. A further research shows that the CPSF7 promotes the malignant development of the ovarian cancer by promoting the proliferation, migration and invasion of the ovarian cancer cells, and the proliferation, migration and invasion of the ovarian cancer cells can be remarkably inhibited by inhibiting the expression of the CPSF7. The invention also finds that UBE2K is one of key downstream targets of the cancer process caused by CPSF7 in the ovarian cancer cell medium, and inhibition of UBE2K expression can weaken proliferation, migration and invasion enhancement effects of the ovarian cancer cells induced by overexpression of the CPSF7. The invention provides a new target for treatment and prognosis prediction of ovarian cancer, and has important clinical application value.

Disclosures herein are directed to methods and compositions for predicting high- and low-risk for liver fibrosis progression in patients. Based on the results achieved from the methods and compositions disclosed herein, liver disease patients can be classified into a prognostic risk group, which enables early diagnosis and prevention of liver fibrosis and other lethal complications. Methods and compositions disclosed herein substantially improve the poor prognosis of subjects having or at risk for one or more liver fibrosis.

The invention belongs to the technical field of biological medicine, discloses a double phenotype hepatocellular carcinoma diagnostic kit and application thereof, and integrates and analyzes DPHCC stem cell heterogeneity through a single-cell multi-omics technology. The characteristics of tumor stem cells (CSCs) of DPHCC are analyzed from a proteome and transcriptome two-dimensional system on the single cell level. And the influence of Non-DPHCC tumor cells in a DPHCC sample is avoided. The correlation between the SPINT2 and the CK19 and the DPHCC is determined, and the SPINT2 is poorly related to the prognosis of the DPHCC. The discovery provides a new target spot for targeting CSCs.

The invention relates to the field of biological medicine, and particularly discloses application of USP32 as a target spot in diagnosis and treatment of triple negative breast cancer. It is found that USP32 is abnormally highly expressed in TNBC and is related to poor prognosis of a patient. Functional experiments show that proliferation and invasion of TNBC cells can be remarkably inhibited and apoptosis of the TNBC cells can be induced by inhibiting USP32, and tumor growth can be effectively inhibited in an animal model. In mechanism, the USP32 stabilizes the key effector factor YAP of the Hippo pathway through the ubiquitination removal effect, the YAP can activate transcription of the USP32 on the contrary, and the USP32 and the YAP form a positive feedback loop to jointly drive the TNBC progress. On the basis, the medicine for targeted inhibition of the USP32 can be used for preparing the medicine for treating the TNBC, and the expression level of the USP32 can also be used as a prognosis diagnosis marker of the TNBC.

This invention relates to the field of biomedical technology, providing the application of ACAT1 in the preparation of diagnostic and prognostic products for non-small cell lung cancer (NSCLC). Compared to existing technologies, the ACAT1 expressed in this invention is decreased in tumor tissues, and this decreased ACAT1 expression is associated with overall survival (OS) and progression-free survival (PFS), indicating a poor prognosis. Therefore, ACAT1 can serve as a biomarker for the diagnosis and prognostic prediction of NSCLC, inhibiting NSCLC cell proliferation and migration. Furthermore, as a key enzyme in β-oxidation, ACAT1 promotes fatty acid oxidation, thereby reducing intracellular lipid accumulation, and has the potential to inhibit disease progression by regulating lipid metabolism in NSCLC.

The invention discloses application of Elov16 as a target spot in preparation of a medicine for treating or preventing colorectal cancer, discovers that Elov16 inhibits colorectal cancer progress through a stearic acid-MFN1 axis, and belongs to the technical field of biology. Elov16 is low in expression in colorectal cancer tissue and predicts poor prognosis, and deletion of Elov16 causes reduction of stearic acid level, and induces enhancement of ubiquitination degradation of mitochondrial fusion protein MFN1 and fragmentation of mitochondria, so that tumor growth is promoted. The exogenous supplement of stearic acid can completely reverse the tumor promoting effect of Elov16 deletion in vivo and in vitro, so that the tumor volume of a mouse is reduced by more than 60%, and the effect has fatty acid specificity. The invention provides preparation application of a medicine taking an Elovl6-stearic acid-MFN1 axis as a target spot, a curative effect prediction kit and a genetic engineering mouse model, establishes an intervention strategy of an Elovl6-stearic acid-MFN1 regulation axis, provides a safe, effective and convenient nutrition intervention new way for precise treatment of colorectal cancer, and has great clinical transformation value.

The application discloses a gene for treating AKT / mTOR signal path related diseases. The application proves through experiments that FAM64A promotes proliferation, invasion, lipid droplet formation and chemotherapy resistance of colorectal cancer through the Akt / mTOR signal path. Up-regulation of FAM64A expression is closely related to occurrence and subsequent development of the colorectal cancer. Abnormal expression of FAM64A can be used as an index of invasive behavior and poor prognosis of the colorectal cancer. The finding provides a new direction for treatment and drug resistance of the Akt / mTOR signal path related diseases, especially treatment and drug resistance of the colorectal cancer.

This invention belongs to the fields of biomedicine and molecular biology, specifically relating to the application of H2AC19 in the detection and treatment of lung adenocarcinoma. Specifically, this invention demonstrates that H2AC19 is abnormally highly expressed in lung adenocarcinoma patients, and this high expression is significantly associated with poor prognosis. Knockout of H2AC19 inhibits angiogenesis and tumor growth in vitro and in vivo, and reduces the proliferation, migration, and tube formation capabilities of lung adenocarcinoma cells in a co-culture model with human umbilical vein endothelial cells. Furthermore, this invention reveals a novel mechanism by which H2AC19 regulates angiogenesis through the p300 / EGR1 / MMP-1 pathway. This invention not only provides a superior method for the diagnosis and prognostic assessment of lung adenocarcinoma, but also lays an experimental foundation and expands new perspectives for the development of highly effective drugs for treating lung adenocarcinoma, thus possessing significant practical application value.

The application discloses a kit for detecting a BMX-ARHGAP fusion gene and application thereof. The application obtains a new fusion gene BMX-ARHGAP from gastric cancer tissues through RNA-seq high-throughput sequencing technology, designs specific primer pairs (SEQ ID NO: 1-2), and establishes a detection method based on RT-qPCR. Research finds that the fusion gene exists in the gastric cancer tissues, and a component part ARHGAP12 is significantly up-regulated in the gastric cancer and is related to tumor infiltration depth; a function experiment shows that ARHGAP12 can promote gastric cancer cell proliferation, migration and invasion; survival analysis shows that high expression of ARHGAP12 is significantly related to poor prognosis of patients. Based on the above findings, the kit can be used for early diagnosis and prognosis evaluation of the gastric cancer, and has a good clinical application prospect.

The invention relates to the technical field of antibody coupling drugs. The invention provides a TM4SF20-targeted antibody coupling medicine as well as a preparation method and application thereof. An antibody comprises VLCDR1, VLCDR2 and VLCDR3 of which the amino acid sequences are shown as SEQ ID NO: 1-3, and VHCDR1, VHCDR2 and VHCDR3 of which the amino acid sequences are shown as SEQ ID NO: 4-6. In-vivo and in-vitro experiments and clinical samples prove that the gene has high specific expression in pancreatic cancer and is related to poor prognosis of pancreatic cancer; a neutralizing antibody alpha-TM4SF20 is designed for a TM4SF20 target spot, and it is verified through a cell internalization experiment that alpha-TM4SF20 can be internalized into cells very well; alpha-TM4SF20 and Dxd are coupled to form an ADC drug, and the effectiveness and safety of the ADC drug are proved through in-vivo and in-vitro experiments.